Intervertebral disc degeneration (IDD) is thought to be the primary cause of low back pain, a severe public health problem worldwide. Current therapy for IDD aims to alleviate the symptoms and does not target the underlying pathological alternations within the disc. Activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway protects against IDD, which is attributed to increase of ECM content, prevention of cell apoptosis, facilitation of cell proliferation, induction or prevention of cell autophagy, alleviation of oxidative damage, and adaptation of hypoxic microenvironment. In the current review, we summarize recent progression on activation and negative regulation of the PI3K/Akt signaling pathway, and highlight its impact on IDD. Targeting this pathway could become an attractive therapeutic strategy for IDD in the near future.
CITATION STYLE
Ouyang, Z. H., Wang, W. J., Yan, Y. G., Wang, B., & Lv, G. H. (2017). The PI3K/Akt pathway: A critical player in intervertebral disc degeneration. Oncotarget. Impact Journals LLC. https://doi.org/10.18632/oncotarget.18628
Mendeley helps you to discover research relevant for your work.